Gil Weitzman
Internal Medicine · New York, NYNPI 1164442968
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 1,034 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,034 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
- Bristol Myers Squibb$1K
- Takeda Pharmaceuticals U.S.A., Inc.$974
- Novo Nordisk$946
- Johnson & Johnson$918
- plus $7K from 42 others
Across 1 payment — averaging $670.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$670
What the payments were for
- Consulting fees$210%
- Food & beverage$20,010100%
- Education$730%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,104 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 12 | $131,095 |
| ZenpepLipase/Protease/Amylase | 21 | $50,380 |
| Dupixent PenDupilumab | 12 | $43,264 |
| MounjaroTirzepatide | 35 | $37,930 |
| CreonLipase/Protease/Amylase | 17 | $37,847 |
| OzempicSemaglutide | 22 | $27,097 |
| LinzessLinaclotide | 37 | $24,077 |
| TrulancePlecanatide | 16 | $15,175 |
| RybelsusSemaglutide | 14 | $12,606 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 61 | $10,453 |
| BelsomraSuvorexant | 14 | $6,010 |
| MotegrityPrucalopride Succinate | 12 | $5,828 |
| Mesalamine ErMesalamine | 28 | $3,097 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,071 |
| Budesonide DrBudesonide | 37 | $2,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $381 | $131,09512 claims |
| AbbVieCreon, Linzess, Synthroid | $4,333 | $63,87473 claims |
| Aimmune Therapeutics, Inc.Zenpep | $91 | $50,38021 claims |
| Novo NordiskOzempic, Rybelsus | $946 | $39,70436 claims |
| Lilly USA, LLCMounjaro | $399 | $37,93035 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $4,049 | $15,17516 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $685 | $10,45361 claims |
| MerckBelsomra | $624 | $6,01014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $974 | $5,82812 claims |
| AstraZenecaSymbicort | $15 | $3,07113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.